uniQure N.V. QURE
21.13 USD -1.90 (-8.23%)
Nov 5, 2026, 12:21 PM EST
20.71 Day range 22.68
8.73 52-week range 51.72
- YTD
- -11.68%
- 1 year
- -18.90%
News
marketbeat.com uniQure Q3 Earnings Call Highlights uniQure NASDAQ: QURE said the FDA has accepted its Biologics License Application for AMT-130, an investigational treatment for Huntington's disease, and granted the application Priority Review with a…
seekingalpha.com uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript
zacks.com uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates uniQure (QURE) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $1.38 per share a year ago.
benzinga.com uniQure Q3 2026 Earnings Call Transcript uniQure (NASDAQ:QURE) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com uniQure Q3 EPS $(0.88) Beats $(0.92) Estimate, Sales $5.200M Miss $6.178M Estimate uniQure (NASDAQ:QURE) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.92) by 4.35 percent. This is a 36.23 percent increase over losses of $(1.38) per…
globenewswire.com uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update ~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~
seekingalpha.com uniQure: The Market May Be Misreading The AMT-130 Four-Year Data (Rating Upgrade) uniQure's stock has come under significant pressure again after the company reported mixed 4-year AMT-130 data. While measurement noise and control bias likely explain much of the disappointing…
benzinga.com FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals The U.S. Food and Drug Administration has accepted uniQure NV's (NASDAQ:QURE) Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's…
benzinga.com FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals FDA grants Priority Review to uniQure for its Huntington's gene therapy, setting a PDUFA target date of May 1, 2027.
globenewswire.com uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease ~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world's first disease-modifying treatment for Huntington's disease ~ LEXINGTON, Mass. and…
zacks.com 3 Promising Genomics Stocks to Add to Your Portfolio Now Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
globenewswire.com uniQure to Announce Third Quarter 2026 Financial Results ~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~
seekingalpha.com uniQure: The Market Graded The Wrong Exam uniQure (QURE) is rated a Speculative Buy with a $47 price target, implying 115% upside. QURE's Huntington's gene therapy BLA is under FDA accelerated review, with a decision expected around November…
newsfilecorp.com uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments New York, New York--(Newsfile Corp. - October 13, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE)…
defenseworld.net uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two…
seekingalpha.com Cedar Grove Capital Q3 2026 Portfolio Update During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican…
businesswire.com UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop NEW YORK--(BUSINESS WIRE)---- $QURE #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:…
defenseworld.net uniQure (NASDAQ:QURE) Stock Price Down 5.5% Following Analyst Downgrade uniQure N.V. (NASDAQ: QURE - Get Free Report)'s share price was down 5.5% on Tuesday after Barclays downgraded the stock from an overweight rating to an equal weight rating. Barclays now has a $28.00…
defenseworld.net Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE) Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the…
defenseworld.net uniQure (NASDAQ:QURE) Shares Gap Down on Analyst Downgrade Shares of uniQure N.V. (NASDAQ: QURE - Get Free Report) gapped down prior to trading on Monday after Barclays downgraded the stock from an overweight rating to an equal weight rating. The stock had…
benzinga.com Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28 Barclays analyst Eliana Merle downgrades uniQure (NASDAQ:QURE) from Overweight to Equal-Weight and lowers the price target from $60 to $28.
benzinga.com RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48 RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:QURE) with a Outperform and lowers the price target from $65 to $48.
schaeffersresearch.com 10 Stocks With Massive Short Squeeze Potential Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
globenewswire.com UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The investigation…
zacks.com uniQure Plunges on Additional Data From Huntington's Disease Study QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.- benzinga.com Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31 Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and lowers the price target from $46 to $31.
benzinga.com Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance…
benzinga.com Crude Oil Down 1%; US Job Openings Fall In August U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.
benzinga.com Why Is uniQure Stock Sinking on Tuesday? uniQure announced long-term trial results for its Huntington's gene therapy, showing slowed disease progression at 36 and 48 months.
benzinga.com Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings U.S. stocks were mixed; Dow and S&P 500 fell while Nasdaq edged up. Carnival beat estimates. BIO-Key surged 127%; oil dropped 2%.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock…
- benzinga.com uniQure Announces Additional Data From Ongoing Phase I/II Studies Of Ifezuntirgene Inilparvovec For Treatment Of Huntington’s Disease; In 12 High-Dose Patients At 48 Months, Both cUHDRS And TFC Continued To Demonstrate Meaningful Slowing Of Disease Progression And Clear Dose-Dependent Response; Primary Endpoint Of cUHDRS Showed 44% Slowing Of Disease Progression ~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS…
benzinga.com uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says uniQure seeks accelerated FDA approval for its Huntington's gene therapy, AMT-130. William Blair resumes coverage with a $73 fair price.
benzinga.com uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the submission of a Biologics License Application…
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
benzinga.com Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75 Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and raises the price target from $60 to $75.
benzinga.com Wolfe Research Upgrades uniQure to Outperform, Announces $65 Price Target Wolfe Research analyst Rudy Li upgrades uniQure (NASDAQ:QURE) from Peer Perform to Outperform and announces $65 price target.- benzinga.com Barclays Maintains Overweight on uniQure, Lowers Price Target to $60 Barclays analyst Eliana Merle maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the price target from $65 to $60.
- benzinga.com uniQure Q2 EPS $(1.22) Misses $(0.82) Estimate, Sales $5.800M Beat $5.467M Estimate uniQure (NASDAQ:QURE) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(0.82) by 48.78 percent. This is a 76.81 percent decrease over losses of $(0.69)…
benzinga.com Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials, Robinhood, Liquidia, Airbnb, Praxis, Alnylam, and Uniqure.
benzinga.com HC Wainwright & Co. Maintains Buy on uniQure, Raises Price Target to $80 HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy and raises the price target from $50 to $80.
benzinga.com What's Going On With Capricor Therapeutics Stock On Friday? Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its Duchenne muscular dystrophy therapy.- benzinga.com Mizuho Maintains Outperform on uniQure, Raises Price Target to $68 Mizuho analyst Uy Ear maintains uniQure (NASDAQ:QURE) with a Outperform and raises the price target from $35 to $68.
benzinga.com Backblaze, Infleqtion, Zeta Global And Other Big Stocks Moving Higher On Tuesday Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal with CoreWeave Inc. Other stocks also gained.
benzinga.com uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related serious adverse events.
benzinga.com Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy application.
benzinga.com uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy - benzinga.com Barclays Upgrades uniQure to Overweight, Raises Price Target to $65 Barclays analyst Eliana Merle upgrades uniQure (NASDAQ:QURE) from Equal-Weight to Overweight and raises the price target from $25 to $65.